Drug Approval | May 10, 2024
Alembic Pharmaceuticals receives 5 USFDA product approvals in Q1 FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Investing in Malaysia's largest clinic operator to expand the healthcare business
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Subscribe To Our Newsletter & Stay Updated
